Skip to main content
. Author manuscript; available in PMC: 2016 Apr 8.
Published in final edited form as: Oncogene. 2015 Jan 26;34(41):5288–5294. doi: 10.1038/onc.2014.455

Figure 5. CT8 treatment enhances the efficacy of HER2 inhibitor therapy.

Figure 5

A. BT474 cells were treated with lapatinib with/without CT8 for the indicated durations of time up to 48 hours. The effects on HER2-HER3 signaling were assayed by western blotting as indicated. B. BT474 cells were treated with the indicated drugs for 72 hours, and the fraction of apoptotic cells quantified by FACS analysis of DNA degradation.